Trial Profile

Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project With Boston Scientific's Innova Drug Eluting Stent

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Mar 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary)
Indications Arterial occlusive disorders; Vascular restenosis
Focus Therapeutic Use
Acronyms MAJESTIC
Sponsors Boston Scientific Corporation

Most Recent Events

08 Mar 2017 Status changed to completed.
22 Feb 2016 According to Boston Scientific Corporation media release, based on data of this (MAJESTIC) trial, Eluvia Stent System received CE Mark approval.
28 Sep 2015 According to Boston Scientific Corporation media release, data from this trial will support global regulatory submission.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com